133 related articles for article (PubMed ID: 11433128)
1. The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial.
Giles TD; Kerut EK; Roffidal LE; Jones R; Given MB; Hutchinson H; Tresznewsky O
Blood Press Monit; 2001 Apr; 6(2):81-4. PubMed ID: 11433128
[TBL] [Abstract][Full Text] [Related]
2. Circadian variation in blood pressure and heart rate in nonhypertensive congestive heart failure.
Giles TD; Roffidal L; Quiroz A; Sander G; Tresznewsky O
J Cardiovasc Pharmacol; 1996 Dec; 28(6):733-40. PubMed ID: 8961069
[TBL] [Abstract][Full Text] [Related]
3. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
[TBL] [Abstract][Full Text] [Related]
4. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
Arch Intern Med; 2001 Jan; 161(2):165-71. PubMed ID: 11176729
[TBL] [Abstract][Full Text] [Related]
5. Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme gene on response to angiotensin-converting enzyme inhibitors in patients with heart failure.
O'Toole L; Stewart M; Padfield P; Channer K
J Cardiovasc Pharmacol; 1998 Dec; 32(6):988-94. PubMed ID: 9869506
[TBL] [Abstract][Full Text] [Related]
6. ACE-inhibitor therapy at relatively high doses and risk of renal worsening in chronic heart failure.
De Vecchis R; Di Biase G; Ariano C; Cioppa C; Giasi A; Ciccarelli A; Pucciarelli A; Cantatrione S
Arq Bras Cardiol; 2011 Dec; 97(6):507-16. PubMed ID: 22001954
[TBL] [Abstract][Full Text] [Related]
7. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
Schwartz JS; Wang YR; Cleland JG; Gao L; Weiner M; Poole-Wilson PA;
Am J Manag Care; 2003 Jun; 9(6):417-24. PubMed ID: 12816171
[TBL] [Abstract][Full Text] [Related]
8. The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure.
Levine TB; Levine AB; Keteyian SJ; Narins B
Clin Cardiol; 1998 Dec; 21(12):899-904. PubMed ID: 9853182
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Packer M; Poole-Wilson PA; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Rydén L; Thygesen K; Uretsky BF
Circulation; 1999 Dec; 100(23):2312-8. PubMed ID: 10587334
[TBL] [Abstract][Full Text] [Related]
10. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling.
Mulder P; Devaux B; Richard V; Henry JP; Wimart MC; Thibout E; Macé B; Thuillez C
Circulation; 1997 Mar; 95(5):1314-9. PubMed ID: 9054865
[TBL] [Abstract][Full Text] [Related]
11. Lisinopril: a review of its use in congestive heart failure.
Simpson K; Jarvis B
Drugs; 2000 May; 59(5):1149-67. PubMed ID: 10852646
[TBL] [Abstract][Full Text] [Related]
12. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
[TBL] [Abstract][Full Text] [Related]
13. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
[TBL] [Abstract][Full Text] [Related]
14. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.
Farquharson CA; Struthers AD
J Am Coll Cardiol; 2002 Mar; 39(5):767-75. PubMed ID: 11869839
[TBL] [Abstract][Full Text] [Related]
15. The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. The APTH Investigators. Ambulatory Blood Pressure and Treatment of Hypertension Trial.
Staessen JA; Bieniaszewski L; Buntinx F; Celis H; O'Brien ET; van Hoof R; Fagard R
Hypertension; 1995 Dec; 26(6 Pt 1):942-9. PubMed ID: 7490153
[TBL] [Abstract][Full Text] [Related]
16. Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.
Davidson NC; Coutie WJ; Webb DJ; Struthers AD
Heart; 1996 Jun; 75(6):576-81. PubMed ID: 8697160
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of the month. The ATLAS study].
Kulbertus H
Rev Med Liege; 1999 Dec; 54(12):952-4. PubMed ID: 10686803
[TBL] [Abstract][Full Text] [Related]
19. Comparison of lisinopril versus digoxin for congestive heart failure during maintenance diuretic therapy. The Lisinopril-Digoxin Study Group.
Herlitz J
Am J Cardiol; 1992 Oct; 70(10):84C-90C. PubMed ID: 1329479
[TBL] [Abstract][Full Text] [Related]
20. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
